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Non-muscle myosin II motor proteins (myosin IIA, myosin IIB, and myosin IIC) belong to
a class of molecular motor proteins that are known to transduce cellular free-energy into
biological work more efficiently than man-made combustion engines. Nature has given a
single myosin II motor protein for lower eukaryotes and multiple for mammals but none
for plants in order to provide impetus for their life. These specialized nanomachines drive
cellular activities necessary for embryogenesis, organogenesis, and immunity. However,
these multifunctional myosin II motor proteins are believed to go awry due to unknown
reasons and contribute for the onset and progression of many autosomal-dominant
disorders, cataract, deafness, infertility, cancer, kidney, neuronal, and inflammatory
diseases. Many pathogens like HIV, Dengue, hepatitis C, and Lymphoma viruses as well
as Salmonella and Mycobacteria are now known to take hostage of these dedicated
myosin II motor proteins for their efficient pathogenesis. Even after four decades since
their discovery, we still have a limited knowledge of how these motor proteins drive cell
migration and cytokinesis. We need to enrich our current knowledge on these fundamental
cellular processes and develop novel therapeutic strategies to fix mutated myosin II
motor proteins in pathological conditions. This is the time to think how to relieve the
hijacked myosins from pathogens in order to provide a renewed impetus for patients’ life.
Understanding how to steer these molecular motors in proliferating and differentiating
stem cells will improve stem cell based-therapeutics development. Given the plethora of
cellular activities non-muscle myosin motor proteins are involved in, their importance is
apparent for human life.
Keywords: myosin II, motor proteins, molecular machines, cell migration, cytokinesis, cancer, pathogenesis,
microparticles
INTRODUCTION
Machines are involved in driving virtually every aspect of mod-
ern human life, and so are myosin motor proteins in driving
cellular life. Myosin motor proteins are specialized molecular
machines that convert cellular free-energy into mechanical work
(Bustamante et al., 2004). It is largely believed that the myosin-
performed mechanical work intersects with almost every facet of
cell biology. In fact, myosins play a central role in driving cel-
lular activities that are necessary for singing a courtship song in
flies, reproduction, childbirth, growth, development, and immu-
nity as well as predisposing humans to a certain degree of risk for
diseases (Stedman et al., 2004; Maravillas-Montero and Santos-
Argumedo, 2012; Slonska et al., 2012; Chakravorty et al., 2014;
Min et al., 2014; Pecci et al., 2014).
The biological cell is equipped with a wide variety of motor
proteins that are divided into cytoskeletal (myosin, kinesin,
dynein), polymerization (actin, microtubule, dynamin), rotary
(F0F1-ATP synthase), and nucleic acid (RNA and DNA poly-
merases, Helicase, Topoisomerases, RSC, SW1/SNF complex,
SMC, viral DNA packaging protein) motor proteins to per-
form specific and dedicated cellular functions (Kolomeisky,
2013; Howard, 2014). Interestingly, these specialized molecular
machines not only operate in a world where Brownian motion
and viscous forces dominate but also work more efficiently than
man-made combustion engines (van den Heuvel et al., 2007;
Kabir et al., 2011). No biological cell can operate in the absence
of these molecular machines. Most of these motor proteins are
ubiquitously expressed but the expression of some of these motor
proteins depends on cell and tissue type. The present review
is about myosin motor protein, an essential component of the
cytoskeletal system that is made up of proteins encoded by 441
genes in human. The human genome contains 40 genes that
encode myosin motor proteins.
The term “myosin” (myo- + -ose + -in) means within mus-
cle and was used to describe proteins with ATPase activity found
originally in striated and smooth muscle cells (Pollard and Korn,
1973). The term “myo” was originated from “mys” to denotemus-
cle in Greek. More than 140 myosins are reported in eukaryotes
except in red algae and diplomonad protists (Vale, 2003). The
majority of myosins have distinct head, neck, and tail domains
and they are categorized into 35 different classes based on phy-
logenic analysis of their conserved heads, domain architectures,
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specific amino acid polymorphisms, and organismal distributions
(Richards and Cavalier-Smith, 2005; Foth et al., 2006; Odronitz
et al., 2007). Each class of myosins received a roman numeral.
If more than one myosin of the same class is expressed in an
organism, they are named in an alphabetical order according to
their discovery. The present review is focused on current under-
standing and recent advances in various aspects of selected class
II myosins as well as their regulation and relevance to human life
and diseases.
CLASS II MYOSINS (MYOSIN II)
More than seven decades ago, an unknown myosin with ATPase
activity was reported in the extracts of muscles (Engelhardt and
Liubimova, 1994). Later, that unknown muscle myosin was iden-
tified as a class II myosin and then called conventional myosin and
or the founding member of myosin super family. Class II myosins
are expressed in all eukaryotes except plants. More than 34 class
II myosins are reported in different organisms to date (Bagshaw,
1993). At least one myosin II is believed to be expressed in all
eukaryotic cells. Based on motor or tail domain sequences and
cell type expressions, class II myosins are further divided into
four different sub-classes or groups. They are (1) Acanthamoeba
or Dictyostelium myosins, (2) yeast myosins, (3) skeletal or car-
diac or sarcomeric myosins, and (4) vertebrate smooth muscle or
non-muscle myosins. Class II myosins are believed to be origi-
nated in unikonts that are ancestral eukaryotes with or without
a single flagellum, including amoebozoans, fungi, and holozoans
(Richards and Cavalier-Smith, 2005). While simple unicellular
organisms like amoeba adopted a single myosin II gene, com-
plexmulticellular organisms exceptDrosophila acquiredmultiples
of them during evolution. The human genome has over 40
myosin genes, and 15 of them are class II myosin genes (MYH1,
MYH2, MYH3, MYH4, MYH6, MYH7, MYH7B, MYH8, MYH9,
MYH10, MYH11, MYH13, MYH14, MYH15, MYH16) but not all
of them are active (Berg et al., 2001). MYH11 encodes myosin II
in smooth muscles but its splice variants result in four distinct
isoforms (Matsuoka et al., 1993). MYH9, MYH10, and MYH14
located on different chromosomes encode myosin IIA, myosin
IIB, and myosin IIC, respectively (Figure 1). These myosin II
motor proteins are expressed exclusively in non-muscle cells,
therefore called non-muscle myosin II motor proteins (Simons
et al., 1991; Toothaker et al., 1991; Leal et al., 2003; Golomb et al.,
FIGURE 1 | Non-muscle myosin II motor proteins. Schematic
representation of myosin II motor proteins that exist as complexes in cells.
2004). Myosin IIA, myosin IIB, and myosin IIC are expressed
in every human non-muscle cell with a few exceptions; how-
ever, their expressions depend on cell and tissue types (Kawamoto
and Adelstein, 1991; Golomb et al., 2004). No tissue or cell type
appears to express all three non-muscle myosin II motor pro-
teins but many cell types express at least one or two of them
under normal physiological conditions. Myosin IIA and myosin
IIB are expressed in endothelial and epithelial cells at similar
levels. However, myosin IIB and myosin IIC are expressed abun-
dantly in nervous and lung tissue, respectively. Myosin IIA is the
only conventional myosin II motor protein expressed in the circu-
lating platelets. Thus, preferential expression of myosin II motor
proteins in different cell types reflects their specialization inmedi-
ating separate, dedicated, and probably non-redundant cellular
functions. Why doesn’t a single cell or tissue type express all three
myosin II motor proteins is yet to be clearly understood. Perhaps,
the cell specific expression of myosin II paralogs is critical for
maintaining different cell and tissue types.
Myosin II motor proteins are mostly found in the cyto-
plasm of quiescent cells except in the nuclei of proliferating
myoblasts (Rodgers, 2005). The cytosolic myosin II motor pro-
teins undergo transient localization to contractile ring during
cytokinesis. Myosin II motor protein using ATP as a cytoso-
lic fuel generates mechanical forces required for separation of
daughter cells during cytokinesis. However, the specific roles and
underlying mechanisms of myosin II paralogs during cytokine-
sis are not clearly understood. The functional and mechanical
roles of non-muscle myosin II motor proteins are extensively
investigated in migrating cells for the past two decades. Many
laboratories reported myosin IIA and myosin IIB with specific
roles in mediating cell shape changes and interaction with matrix
during migration. Cells prefer to make periodic extension and
retraction of their lamellipodia during migration by unknown
mechanisms. Interestingly, myosin IIA and myosin IIB motor
proteins localize distinctly in the lamellipodia of migrating cells.
On one hand, myosin IIB promotes lamellipodia and growth cone
extensions and on the other, myosin IIA drives retraction of cell
membrane during cell migration (Rochlin et al., 1995; Brown and
Bridgman, 2003; Betapudi, 2010). The specific roles of myosin
IIC motor protein in driving cell migration are not clearly under-
stood. Myosin II activity is necessary for keratinocytes’ migration,
a critical step in the re-epithelialization of human skin wound
(Betapudi et al., 2010). Myosin II motor proteins are also required
for internalization of the cell surface receptors including EGFR
and CXCR4 (Rey et al., 2007; Kim et al., 2012). Myosin II-
mediated mechanical forces have been implicated in operating
the activity of contractile vacuoles to expel additional water and
toxic materials from the soil-living amoeba in hypo-osmotic con-
ditions (Betapudi and Egelhoff, 2009). Myosin II motor proteins
have also been implicated in the mediation of viral infection (van
et al., 2002; Arii et al., 2010), microparticle secretion (Betapudi
et al., 2010), and cell death (Solinet and Vitale, 2008; Flynn and
Helfman, 2010; Tang et al., 2011), however, their specific roles
and underlying mechanisms remain unclear. Lower eukaryotes,
such as amoeba can survive with certain developmental defects
in the absence of myosin II (Xu et al., 1996) but the expres-
sion of all three myosin II motor proteins are necessary for
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mouse embryo growth and development (Conti and Adelstein,
2008).
NON-MUSCLE MYOSIN II COMPLEX
In line with multiple components involved in the assembly of
man-made machines, biological cells also build their molecular
machines using multiple polypeptides that are encoded by dif-
ferent genes. For instance, myosin II motor protein exists as a
complex consisting of six non-covalently associated polypeptides
that are encoded by a single myosin II and two different non-
myosin genes. Each myosin II complex with 525 kDa molecular
weight is composed of a myosin II heavy chain (MHC) homod-
imer, two essential light chains (ELC), and two regulatory light
chains (RLC). Based on their extraction methods, ELC and RLC
are also called alkali and 5,5′-dithiobis/2-nitrobenzoate (DTNB)
light chains, respectively. While MHC with 226 kDa molecular
weight is encoded by a myosin II gene, both ELC with 16 kDa
and RLC with 22 kDa molecular weights are considered as non-
myosin proteins of myosin II complex. Both ELC and RLC are
commonly found in all myosin II complexes. Alternatively spliced
MHC, ELC, and RLC are known to be expressed in certain tissue
but our current knowledge on their specificities is still limited.
Both heavy and light chain peptides undergo the UCS (UNC-
45/Cro1/She4) chaperone-mediated proper folding and assembly
regulation in order to form a functional myosin II complex
in the Golgi apparatus (Gazda et al., 2013; Hellerschmied and
Clausen, 2013). This understudied complicated assembly process
is common for all three myosin II motor proteins remains elu-
sive. Transcriptional regulations of ELC and RLC are not clearly
understood; however, MHC expressions of all three myosin II
motor proteins are under the control of house-keeping pro-
moters having no TATA elements (Kawamoto, 1994; Weir and
Chen, 1996). However, differential expressions of MHCs were
observed in response to serum andmitotic stimulants (Kawamoto
and Adelstein, 1991; Toothaker et al., 1991). Elevated levels of
MHCs were found in many types of tumor tissues (our unpub-
lished results) but their underlying mechanisms are not clearly
understood.
The MHC of class II myosins can be subdivided into dis-
tinct head, neck, and tail functional domains. Except C-terminal
tail pieces, the MHCs of myosin IIA, myosin IIB, and myosin
IIC share a significant protein sequence similarity in their motor
domains. The N-terminal catalytic globular head or motor
domain has binding sites for actin and ATP. Motor domain is
also called the functional engine of myosin II motor protein.
Myosin II motor domain undergoes an ATP-dependent confor-
mational change in order to control its interaction with actin
filaments, a key element of the cell strategy to convert cellular
free-energy into proteinmotion ormechanical work. Despite hav-
ing a significant sequence similarity, myosin II motor domains
carry different binding affinities for actin filaments. Thus, myosin
IIA, IIB, and IIC are believed to perform mechanical work with
different energetic efficiencies in cells. Myosin II motor domain
is followed by a neck region consisting of two conserved IQ
motifs (IQxxxRGxxxR); however, myosins of other classes may
have more or less than two IQ motifs (Cheney and Mooseker,
1992). IQ motifs form an amphiphilic uninterrupted seven-turn
α-helix with binding affinity for either light chains or calmodulin
in Ca+2-independent manner. ELC and RLC occupy the first and
second IQ motifs of the neck region, respectively. ELC binds IQ
motif to give stability forMHC; however, RLC offers both stability
and functional regulation toMHC. IQ domain allows light chains
to acquire either compact or extended conformation. Thus, neck
region with light chains attached acts as a linker and lever arm
for myosin II motor domain to amplify energy conversion into
mechanical work. The length of the neck region is believed to have
direct impact on myosin II motor speed and energy transduction
into mechanical work (Uyeda et al., 1996). The neck region of all
myosins have IQ motifs except class XIV Toxoplasma myosin A
(Heintzelman and Schwartzman, 1997). IQ motif with approxi-
mately 25 amino acids in length is widely distributed in nature,
thus, ELC also binds other myosins of class V, VI, and VII as well
as non-myosin proteins carrying IQ motifs, but RLC exclusively
binds to myosins of class II and XVIII (Chen et al., 2007; Tan
et al., 2008). Myosin II neck region is followed by a tail domain
with variable amino acid sequences. The tail domain with coiled-
coil α-helices terminates into a short non-helical tailpiece. The
coiled-coil tail domain undergoes homodimerization to form a
single rod-like structure. Thus, myosin II complex has two glob-
ular heads or motor domains with a single coiled-coil rod-like
structure hence called double-headed myosin II motor protein.
Myosin II complex attains a compact folded conformation due
to a “proline-kink” at the junction of head and rod domains,
and attachment of its C-terminal tail domain to RLC as depicted
in Figure 1 (Onishi and Wakabayashi, 1982; Trybus et al., 1982;
Craig et al., 1983). Thus, the myosin II complex with compact
folded structure sediments at 10 S (Svedberg) and therefore called
10S form. The myosin II complex in 10S form shows high bind-
ing affinity for ADP and inorganic phosphate (Pi), and virtually
no enzyme activity (Cross et al., 1986, 1988). However, the acti-
vated myosin II complex exists in an elongated conformation
due to its C-terminal tail detachment from RLC. The activated
myosin II complex in an elongated form sediments at 6 S and
therefore called 6S form (Trybus and Lowey, 1984). Myosin II
motor proteins with elongated conformation tend to assemble
into highly ordered parallel and anti-parallel thick filaments due
to intermolecular interactions between coiled-coil tail domains.
Interestingly, myosin II tail domains form large aggregates with-
out proper filamentation in the absence of RLC (Pastra-Landis
and Lowey, 1986; Rottbauer et al., 2006). Thus, RLC-controlled
tail-domain filamentation and motor domain interaction with
actin filaments are the most important aspects of cell strategy for
converting ATP released free-energy into force and mechanical
work using myosin II motor proteins.
RLC PHOSPHORYLATION IN REGULATING MYOSIN II
ACTIVITY
Myosin IIA, myosin IIB, and myosin IIC paralogs with 60–80%
sequence similarity at the amino acid level and same quaternary
structure appear to be diverged from a common ancestor more
than 600 million years ago, however, they display different regu-
latory mechanisms under normal physiological conditions (Jung
et al., 2008). Role of RLC phosphorylation in regulating myosin
II activity in many cell and tissue types is extensively investigated
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since its discovery in rabbit skeletal muscle myosins more than
three decades ago (Casadei et al., 1984). RLC perhaps does not
exist alone but when remains associated with the neck region
of MHC undergoes reversible phosphorylation on its S1, S2, T9,
T18, and S19 amino acids in order to turn-on and turn-off myosin
II motor complexes in cells (Figure 2). RLC phosphorylation on
S19 alone or on both T18 and S19 amino acids turns-on myosin
II motor complex by increasing its ATPase activity and extended
6S conformation that allows simultaneous assembly into thick fil-
aments (Wendt et al., 2001; Somlyo and Somlyo, 2003; Betapudi
et al., 2006, 2010). However, RLC phosphorylation does not affect
myosin II motor domain affinity for actin filaments (Sellers et al.,
1982). RLC phosphorylation on S1, S2, and S9 or dephosphory-
lation on T18 and S19 amino acids turns-off myosin II complex
by allowing acquisition ofmonomeric 10S compact conformation
and no filamentation.
RLC reversible phosphorylation is tightly regulated by both
myosin specific phosphatase and a wide variety of kinases includ-
ing myosin light chain kinase (MLCK/MYLK), Rho-associated
coiled-coil-containing kinase (ROCK), leucine zipper interact-
ing protein kinase (ZIPK) or death associated protein kinase 3
(DAPK3), citron kinase or citron rho-interactive kinase (CRIK)
or Serine/threonine-protein kinase 21 (STK21), myotonic dystro-
phy kinase-related CDC42-binding kinase (MRCK/CDC42BP).
These kinases are known to phosphorylate RLC on T18 and S19
amino acids to activate myosin II complexes in different cell types.
Protein kinase C (PKC) phosphorylates S1, S2, and S3 amino
acids to inactivate myosin II in dividing cells (Nishikawa et al.,
1984; Varlamova et al., 2001; Beach et al., 2011). Interestingly,
all these kinases display specific intracellular localizations and
respond to a wide variety of signal transduction pathways in order
to phosphorylate RLC and activate myosin II motor proteins in
many cell types. MLCK in response to Ca+2-calmodulin acti-
vates myosin II that is localized next to cell membrane (Totsukawa
et al., 2004). The site-specific intracellular localization and activ-
ity of MLCK are regulated by several kinases including p21
activated kinase 1 (PAK1), Abl tyrosine kinase, Src, and arrest
defective 1 in many cell types (Sanders et al., 1999; Dudek et al.,
2004; Shin et al., 2008). RhoA, a small GTP-binding protein acti-
vates both ROCK and citron kinase in the central part of cell.
The actin binding protein, Shroom3 directs ROCK intracellular
FIGURE 2 | Mechanism of the activation of myosin II motor proteins.
RLC phosphorylation by MLCK and ROCK or other kinases turns on myosin
II motor protein in vivo.
localization, and RLC phosphorylation in neuroepithelial cells
(Haigo et al., 2003; Hildebrand, 2005). DAPK3 predominantly
displays nuclear localization and phosphorylates RLC in the cells
that are undergoing apoptosis in a Ca2+/calmodulin-independent
manner (Murata-Hori et al., 1999). PKC phosphorylates RLC in
the presence of Ca+2 and DAG (diacylglycerol) and or phorbol
esters in mitotic cells (Varlamova et al., 2001). Both intracellular
site-specific RLC reversible phosphorylation and myosin II acti-
vation are tightly controlled by protein phosphatase 1 (PP1), a
ubiquitously expressed myosin specific phosphatase (Xia et al.,
2005; Matsumura and Hartshorne, 2008; Rai and Egelhoff, 2011).
All the regulators of RLC phosphorylation are also known to
phosphorylate other substrates in cells. For instance, MLCK is
implicated in phosphorylating a proline-rich protein tyrosine
kinase 2 (PYK2/PTK2B) or focal adhesion kinase 2 (FAK2) that is
involved in promoting lung vascular endothelial cell permeability
during sepsis (Xu et al., 2008). ROCK also directly phosphory-
lates LIM kinase and MYPT1, a regulatory subunit of PP1 in
many types of cells and tissues (Kimura et al., 1996; Leung et al.,
1996). MYPT1 phosphorylation inactivates PP1 and this leads to
a marked increase in RLC phosphorylation and myosin II activa-
tion. MYPT1 phosphorylation is also regulated by ZIPK, MRCK,
and PKC in many cell and tissue types. PKC also phosphory-
lates MHC to regulate myosin II activity in cells under normal
physiological conditions. MLCK-A is the only RLC phosphory-
lating kinase identified inDictyostelium to date (Tan and Spudich,
1990). Unlike MLCK in mammalian cells, MLCK-A phosphory-
lates S13 of RLC in the absence of Ca+2-calmodulin (Tan and
Spudich, 1990). The RLC phosphorylation on S13 amino acid
increases myosin II motor activity and regulates cell morpho-
logical changes without affecting normal growth and develop-
ment of amoeba (Griffith et al., 1987; Chen et al., 1994; Uyeda
et al., 1996; Liu et al., 1998; Matsumura, 2005). Except reversible
phosphorylation, no other posttranslational modification of
RLC that has a role in regulating myosin II activity is known
to date.
MHC PHOSPHORYLATION IN REGULATING MYOSIN II
ACTIVITY
MHC phosphorylation was first reported in macrophages in
the early 1980s and after nearly a decade its role in regulat-
ing myosin II filamentation and localization was documented in
lower eukaryotes like Acanthamoeba and Dictyostelium disoideum
(Collins and Korn, 1980; Kuczmarski and Spudich, 1980; Trotter,
1982; Kuznicki et al., 1983; Trotter et al., 1985; Barylko et al.,
1986; Pasternak et al., 1989; Egelhoff et al., 1993). According
to computational prediction of phosphorylation sites, the heavy
chains of myosin IIA, IIB, and IIC appear to undergo phos-
phorylation on multiple residues in the head, neck, and tail
domains; however, only a few sites in the coiled-coil and non-
helical tail regions of their C-terminal ends are reported to date.
The MHC of myosin IIA undergoes phosphorylation on T1800,
S1803, and S1808 in the coiled-coil and on S1943 residues in the
non-helical tail regions (Figure 3). Myosin IIB and myosin IIC
heavy chains also undergo phosphorylation on multiple sites in
the coiled-coil and non-helical tail regions of their C-terminal
ends (Dulyaninova and Bresnick, 2013). Many kinases including
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FIGURE 3 | Myosin II motor proteins-mediated mechanotransduction
in cells. Several myosin II heavy chain specific protein kinases activate
myosin II motor proteins. The activated myosin II associates with actin
filaments to generate contractile forces using cellular ATP.
casein kinase 2 (CK2), the members of PKC as well as alpha-
kinase family are involved in phosphorylating C-terminal ends of
all three MHCs in normal physiological and pathological condi-
tions (Murakami et al., 1998; Dulyaninova et al., 2005; Clark et al.,
2008a,b; Ronen and Ravid, 2009). PKC members are involved in
phosphorylating S1916 and S1937 residues of myosin IIA and
myosin IIB, respectively (Conti et al., 1991; Even-Faitelson and
Ravid, 2006). PKC is also involved in phosphorylating other mul-
tiple serine residues in myosin IIB and threonine residues in
myosin IIC coiled-coil regions (Murakami et al., 1998; Ronen and
Ravid, 2009). CK2 is known to phosphorylate S1943 residue in
the non-helical tail region of myosin IIA in vitro. CK2 was impli-
cated in the regulation of myosin II assembly and localization
especially in pathological conditions. However, neither chemi-
cal inhibition nor siRNA-mediated depletion of CK2 showed any
effect on S1943 phosphorylation or breast cancer cell migration
on fibronectin coated surfaces (Betapudi et al., 2011). CK2 is
also involved in phosphorylating multiple residues in the coiled-
coil and non-helical tail regions of myosin IIB and myosin IIC
(Murakami et al., 1998; Ronen and Ravid, 2009; Rosenberg et al.,
2013). Thus, CK2 clearly plays a critical role in regulating myosin
II-mediated cellular functions in other pathological conditions.
In addition to PKC and CK2, several members of the alpha-
kinase family are involved in phosphorylating myosin II heavy
chains in mammals and Dictyostelium discoideum. Alpha kinases
belong to a small and unique group of protein kinases with cat-
alytic domains having a little or no similarity at amino acid
level with the catalytic domains of conventional protein kinases
(Ryazanov et al., 1999; De la Roche et al., 2002; Drennan and
Ryazanov, 2004; Scheeff and Bourne, 2005; Middelbeek et al.,
2010). Conventional protein kinases usually find their phospho-
rylating sites in β-turns, loops, and irregular structures of their
substrates; however, the first member of the alpha-kinase family
prefers to phosphorylate amino acids located in the α-turns of
their cellular targets hence called α-kinases (Vaillancourt et al.,
1988; Luck-Vielmetter et al., 1990). But recent in vitro phospho-
rylation studies showed that alpha-kinases also target residues
present in the non-alpha helical structures of their cellular sub-
strates (Jorgensen et al., 2003; Clark et al., 2008a). Members
of the alpha-kinase family are identified only in eukaryotes to
date (Ryazanov et al., 1999; Scheeff and Bourne, 2005). Transient
receptor potential melastatin 6 (TRPM6) and Transient receptor
potential melastatin 7 (TRPM7) kinases are among the total six
alpha-kinases identified in human to date. TRPM6 and TRPM7
kinases belong to a large protein family of transient receptor
potential cation channels that are involved in sensing mechanical
stress, pain, temperature, taste, touch, and osmolarity (Ramsey
et al., 2006; Middelbeek et al., 2010; Su et al., 2010; Runnels,
2011; Mene et al., 2013). Both TRPM6 and TRPM7 kinases
phosphorylate T1800, S1803, and S1808 residues in the coiled-
coil region of MHC to control myosin IIA filamentation and
association with actin filaments (Clark et al., 2008a,b). These
multifunctional kinases also phosphorylate several residues in the
non-helical tail regions of myosin IIB and myosin IIC to con-
trol myosin II filamentation. MHC undergoes phosphorylation
on T1823, T1833, and T2029 residues in the tail region of myosin
II in Dictyostelium (De la Roche et al., 2002). Phosphorylation of
these sites controls myosin II filamentation and plays critical roles
in regulating growth and development of Dictyostelium. Except
vWKa kinase, all other identified alpha-kinase family members
including MHCK-A, MHCK-B, MHCK-C, and MHCK-D are
involved in phosphorylating these sites in Dictyostelium (Egelhoff
et al., 2005; Yumura et al., 2005; Underwood et al., 2010).
Although vWKa does not directly phosphorylate MHC in vitro
but regulates myosin II expression and filamentation in cells
by unknown mechanism (Betapudi et al., 2005). Unlike other
alpha kinases involved in regulating myosin II, vWKa displays
specific sub-cellular localization to contractile vacuoles that are
known to expel toxic metals and excess water from the cyto-
plasm of amoeba. Though the underlying mechanisms are yet to
be uncovered, the myosin II-mediated mechanical work has been
implicated in regulating the dynamics of contractile vacuoles and
survival of Dictyostelium discoideum in abnormal osmotic condi-
tions (Betapudi and Egelhoff, 2009). vWKa regulates myosin II
expression and filament disassembly by unknown mechanisms
to protect amoeba from osmotic shock death (Betapudi and
Egelhoff, 2009). Phosphatases specific to the heavy chains of
myosin II motor proteins are yet to be identified in mammals.
Many proteins including S100A4, lethal giant larvae (Lgl),
myosin binding protein H, and S100P bind MHCs to control
phosphorylation and filament assembly of myosin II in flies and
mammals (Kriajevska et al., 1994; Ford et al., 1997; Vasioukhin,
2006; Du et al., 2012; Hosono et al., 2012). Lgl is a tumor sup-
pressor protein and forms a complex with C-terminal ends of
the MHC of myosin II to control cell proliferation. However, the
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Lgl-myosin II complex dissociates when myosin II heavy chain is
phosphorylated by PKC (Strand et al., 1994; Kalmes et al., 1996;
Plant et al., 2003; Betschinger et al., 2005). Lgl binds coiled-coil
regions of the MHC to control myosin II filamentation and local-
ization (De et al., 1999; Dahan et al., 2012). Deletion of the Lgl
located specific region in the human chromosome 17 has been
implicated in the development of Smith-Magenis Syndrome, a
developmental disorder that affects many body parts, intellec-
tual disability, and sleep disturbances (Smith et al., 1986; Koyama
et al., 1996; De et al., 2001). However, role of mutated Lgl in con-
trollingmyosin II phosphorylation and cellular functions remains
elusive. The metastasis factor mts1 also called S100A4 or calvas-
culin, a member of the S100 family of calcium-binding proteins,
binds C-terminal ends of the MHC of myosin II. Binding of
S100A4 to C-terminal ends of the MHC promotes phospho-
rylation on S1943 and disassembly of myosin II filamentation;
however, the underlying mechanisms remain unknown to date
(Li et al., 2003; Badyal et al., 2011; Mitsuhashi et al., 2011;
Kiss et al., 2012). S100-P, another member of S100 family of
calcium-binding proteins and a novel therapeutic target for can-
cer, interacts with myosin II in cells. S100-P has been implicated
in controlling myosin II filamentation and cell migration (Du
et al., 2012). Myosin binding protein H (MYBPH) binds ROCK1
to control RLC phosphorylation and cell migration. MYBPH also
bindsMHC to control myosin II filamentation and cell migration;
however, the underlying mechanisms are not clearly understood
(Hosono et al., 2012). Recent studies suggest that the unassem-
bled myosin II with phosphorylated RLC plays a role in the
initiation of focal adhesion complexes formation and cell mem-
brane extension (Shutova et al., 2012). It would be interesting to
understand the coordinated regulation of RLC and MCH phos-
phorylation adopted by cell to regulate myosin II filamentation
and cellular functions. Though the underlying mechanisms are
not clearly understood, Tropomyosin, an integral part of the actin
cytoskeleton system in cells has been implicated in regulating
myosin II localization to plasma membrane and stress fiber for-
mation (Bryce et al., 2003). Myosin II activity is also controlled by
Supervillin, an actin filament binding and cell membrane associ-
ated scaffolding protein. Supervillin binds MLCK to control RLC
phosphorylation and myosin II activity (Takizawa et al., 2007).
Thus, non-muscle myosin II motor proteins are regulated by
several proteins at multiple levels to perform dedicated cellular
functions.
MYOSIN II MOTOR PROTEINS IN PREDISPOSING HUMANS
TO DISEASES
Plants live normal life without class II myosins but mammals
require these multifunctional molecular machines for survival
and growth. Because the MYH9 germline-ablated mice with-
out myosin IIA die on 6.5 embryonic day (E) due to defective
cell-cell interaction and lack of polarized visceral endoderm
(Conti et al., 2004). The MYH10 germline-ablated mice with
no myosin IIB survive till E14.5 and then die due to brain
and cardiac developmental defects (Tullio et al., 1997, 2001).
However, the MYH14-ablated mice in the absence of myosin IIC
can survive with no obvious defects till adulthood but require
the expression of myosin IIB (Ma et al., 2010). Misregulation,
mutations, and alternative splicing of MYH9, MY10, and MY14
predispose humans to the onset and progression of many dis-
eases (Table 1). More than 45 mutations are identified in MYH9
to date and some of them are linked to a large number of
autosomal-dominant disorders including May-Hegglin anomaly,
Sebastian platelet syndrome, Fetchner syndrome, Bernard-Soulier
syndrome, Alport syndrome, and Epstein syndrome. These dis-
eases are collectively called MYH9-related diseases (MYH9RD)
(Kelley et al., 2000; Burt et al., 2008; Pecci et al., 2008; Balduini
et al., 2011). The MYH9RD patients with mutations in the
motor domain (R702C/H and R1165C/L) of myosin IIA develop
deafness, cataract, Döhle-like inclusions, nephritis, and throm-
bocytopenia with enlarged platelets in their middle age (Pecci
et al., 2008, 2014; De et al., 2013). An estimated 30–70 percent
of MYH9RD patients develop kidney disease in their early adult-
hood. Leukocytes of the MYH9RD patients carry non-functional
myosin IIA clumps. However, patients carrying mutations in
the tail domain of myosin IIA (D1424H/N/Y, V1516M, E1841K,
R1933X) show no symptoms of clinical relevance (Pecci et al.,
2010). The overexpression of myosin IIA is implicated in caus-
ing enhanced cancer cell migration and metastasis as well as lung
and kidney tumor invasion (Gupton andWaterman-Storer, 2006;
Derycke et al., 2011; Xia et al., 2012). However, this hypoth-
esis is downplayed by recent reports on myosin IIA roles in
the posttranscriptional stabilization of p53 activity and repres-
sion of squamous cell carcinoma in mice (Schramek et al.,
2014). A chimeric MYH9-Alk transcript formed by the fusion
of MYH9 and ALK (anaplastic lymphoma kinase) was observed
in anaplastic large cell lymphoma but its disease relevance is
yet to be established (Lamant et al., 2003). No mutation in
MYH10 that is relevant to a disease with any clinical symptom
is reported to date; however, recently an E908X de novo muta-
tion is reported in patients with microcephaly, hydrocephalus,
cerebral, and cerebellar atrophy. An indirect link in between the
expression of myosin IIB and progression of several diseases
including, megakaryopoiesis, myocardial infarction, scar tissue
formation, demyelination, and juvenile-onset neuronal ceroid
lipofuscinosis (JCNL) or Batten disease is established (Antony-
Debre et al., 2012). Batten disease, a lysosomal storage disorder
is caused by mutations in CLN3 that encodes a lysosomal mem-
brane binding chaperone known to interact directly with myosin
IIB. Mutations in CLN3 are believed to affect interaction with
myosin IIB as well as retrograde and anterograde trafficking
in the Golgi complexes (Getty et al., 2011). Patients carrying
CLN3 mutations show symptoms of seizures, psychomotor dis-
turbances, dementia, and loss of vision (Cotman and Staropoli,
2012). Patients carrying mutations in MYH14 are also linked to
many diseases including hereditary blindness (DFNA4), hoarse-
ness, peripheral neuropathy, andmyopathy (Donaudy et al., 2004;
Choi et al., 2011). In addition, patients expressing aberrant splic-
ing products of MYH14 develop myotonic dystrophy type 1
(DM1), a progressive multisystem genetic disorder that affects
1 in 8000 people worldwide (Rinaldi et al., 2012; Kumar et al.,
2013).
In addition, the overexpression of myosin II upstream regula-
tors ROCK andMts1 is implicated in spreading cancer (Sandquist
et al., 2006; Boye and Maelandsmo, 2010; Kim and Adelstein,
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Table 1 | Defects and associated diseases of myosin II motor proteins and their regulators.
Gene Mutation/Defect Disease Common symptoms
MYH9 R702C/H R1165C/L and
many*
MYH9RD (May-Hegglin anomaly, Sebastian platelet syndrome,
Fetchner, Bernard-Soulier syndrome, Alport syndrome, Epstein
syndrome)
Thrombocytopenia, enlarged platelets,




Anaplastic large cell lymphoma Blood cancer, painless swelling of lymph
nodes, and rapid weight loss.
Overexpression$ Cancer metastasis –
MYH10 E908X (de novo) Microcephaly, hydrocephalus, cerebral and cerebellar atrophy Small head, dwarfism or short stature,
delayed motor, and speech functions.
Downregulation Megakaryopoiesis, myocardial infarction, demyelination, Batten
disease
Chest pain, dizziness, nausea, ocular
paralysis, speech problem, and impaired
vision.
MYH14 S7X, S120L, G376C,
R726S, L976F
Hereditary blindness, hearing impairment (DFNA4), peripheral
neuropathy, myopathy, hoarseness
Deafness, loss of vision, burning pain,
numbness, changes in skin, hair or nail,
dizziness, and paralysis.
Aberrant splicing Myotonic dystrophy type 1 (DM1) or Steinert disease Weakness.
ROCK Overexpression$ Cancer metastasis –
Mts1 Overexpression$ Cancer metastasis –










CLN3@ L101P, L170P, Y199X,
Q295K
Seizures, dementia, and psychomotor disturbances Loss of vision and memory, mood swings,
poor judgment.
TRPM6 R56X, S141L, R484X,
S590X, 427–429,
736–737, 1260–1280
Seizures, Hypocalcemia, tetany, hypomagnesemia Abnormal eye movement, convulsions,
fatigue, numbness, anxiety, depression,
dementia.
LLgl 17p11.2ˆ Smith-Magenis Syndrome Intellectual disability, sleep disturbances,
behavior problems, defects in many body
parts.
*Refer Burt et al. (2008), **Found in the lymphocytes of lymphoma patients, $Implicated, #Encodes RLC in Drosophila, @Interacts directly with myosin IIB,
 deletion, SNP, single nucleotide polymorphism; ∧LLgl, located region in chromosome 17.
2011). Mutations in RLC were shown to affect singing male
courtship song in flies (Chakravorty et al., 2014). Mutations in
RLC phosphorylating MYLK are linked to cancer (Greenman
et al., 2007) and familial aortic dissections that may cause sudden
death (Wang et al., 2010). A few race-specific single nucleotide
polymorphism variants of MYLK are linked to asthma, acute
lung injury and sepsis (Gao et al., 2006, 2007; Flores et al.,
2007). Hypomagnesemia patients with secondary hypocalcemia
carry mutations in TRPM6 that is known to regulate MHC
phosphorylation (Schlingmann et al., 2002; Walder et al., 2002).
Though the underlying mechanisms are not clearly understood,
myosin II motor proteins are believed to be hijacked by many
pathogens such as herpes simplex virus type 1 for egression
(van et al., 2002; Arii et al., 2010), murine leukemia virus
for infection (Lehmann et al., 2005), and Salmonella bacteria
for growth in macrophages (Wasylnka et al., 2008). Kaposi’s
sarcoma herpes simplex virus that is known to cause AIDS related
neoplasm manipulates c-Cbl and myosin II-mediated signaling
pathway to induce macropinocytosis in order to infect blood
vessels (Sharma-Walia et al., 2010). Some pathogens like HIV-
1 selectively down-regulates myosin IIA in kidney and cause
renal disease probably to escape clearance through urine (Hays
et al., 2012). Dengue virus type 2 activates Rac1 and Cdc42-
mediated signaling pathway to regulate myosin II for successful
infection of host cells (Zamudio-Meza et al., 2009). Respiratory
Syncytial Virus (RSV) that is known to cause severe respira-
tory tract infections is believed to activate actomyosin system
for improved pathogenesis (Krzyzaniak et al., 2013). Pathogens
like hepatitis C virus induce development of autoantibodies
having binding affinity for myosin IIA perhaps as a part of
escape strategy from host defense network (von Muhlen et al.,
1995).
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CONCLUSION AND PERSPECTIVES
Molecular motor proteins are largely accepted as the most effi-
cient transducers of cellular free energy into biological work that
is critical for the sustenance of life. Class II myosins especially
non-muscle myosin IIA, myosin IIB, and myosin IIC motor pro-
teins are emerged as themainmechanotransducers of cellular-free
energy that is necessary for driving multiple biological processes
ranging from birth to death in mammals’ life. During the past
two decades, research on myosin II motor proteins was focused
on understanding the underlying mechanisms of myosin II-
mediated mechanotransduction in many biological systems. It is
also proven beyond reasonable doubt that murine life does not
exist without the expression of non-muscle myosin II motor pro-
teins (Conti and Adelstein, 2008). Interestingly, many patients
with mutated myosin IIA, myosin IIB, and myosin IIC paralogs
are reported but none without these biological nanomachines to
date. The extrapolation of these findings with caution may sug-
gest that life in mammals does not exist without the expression of
non-muscle myosin II motor proteins. Therefore, the emergence
of genes that encode non-muscle myosin II motor proteins per-
haps is a turning point in the evolution of mammals. During this
process, humans acquired three different genes Myh10, Myh11,
and Myh14 with a significant homology in nucleotide sequence.
It is generally believed that humans do require the expression
of all three functional non-muscle myosin II motor proteins to
maintain normal growth, development, and disease resistance.
But why human cell and tissue types display differential expres-
sion of myosin II paralogs still remains unanswered. Part of the
reasons could be due to their specialization in mediating ded-
icated functions that are specific to each cell and tissue type.
However, this concept will benefit from further understand-
ing of structural and posttranslational modifications of all three
different myosin II complexes. Although we made progress in
identifying several mutations in myosin II motors proteins and
their regulating proteins, very little is known about the disease-
relevant mutations in myosin II motor proteins. Novel strategies
for management and diagnosis of MYH9RD patients are required
(Althaus and Greinacher, 2010). This area of research requires
additional attention to gain more insights for the development
of myosin II-based novel therapeutic approaches in future. Many
modern cell biologists recognize myosin II motor proteins as key
drivers of cell migration and cytokinesis that are known to go
awry in cancer and other pathological conditions. Although over-
expression of myosin II motor proteins has been implicated in
driving cancer progression and metastasis, further understand-
ing of their specific expression profiles in every cancer type will
help designing therapeutic developments. Also, expanding our
limited knowledge on the expression of chimeric as well as alter-
nate splicing products of non-muscle myosin II motor proteins
in pathological conditions will allow development of treatment
options. During the past two decades, we made a very limited
progress on understanding how pathogens hijack non-muscle
myosin II motor proteins for their efficient infection and prop-
agation. Understanding what made these dedicated molecular
machines to work for the interests of pathogens is no less than
a challenge to cell biologists in future. We are yet to understand
how myosin II motor proteins mediate release of microvesicles
that are known to make inter cellular communications and pro-
mote progression of many human diseases. Myosin II-mediated
mechanotransduction has been implicated in the regulation of
stem cell proliferation and differentiation (Chen et al., 2014).
Additional efforts to understand the mechanical roles of myosin
IIA, IIB, and IIC motor proteins will have a significant impact on
stem cells-based tissue engineering, synthetic bioengineering, and
therapeutic development.
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